Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older

Paul J. Hampel, MD, Timothy G. Call, MD, Kari G Rabe, Sara J. Achenbach, Eli Muchtar, MD, Saad S. Kenderian, MB, ChB, Yucai Wang, MDPhD, Amber B. Koehler, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Min Shi, MDPhD, Curtis A. Hanson, MD, Tait Shanafelt, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Wei Ding, MD PhD, Sameer A. Parikh, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137578

Published: 2020

Journal Articles

Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139068

Published: 2020

Journal Articles

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Geffen Kleinstern, PhD, J. Brice Weinberg, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Dennis P. Robinson, Aaron D. Norman, MPH, Kari G Rabe, Celine M. Vachon, PhD, Connie E. Lesnick, Timothy G. Call, MD, Danielle M. Brander, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Richard R. Furman, MD, Tait Shanafelt, MD, Susan L. Slager, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-136548

Published: 2020

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

William J Archibald, MDCPA, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Curtis A. Hanson, MD, Wei Ding, MD PhD, Amber Koehler, PA-C, MS, Eli Muchtar, MD, Suzanne R. Hayman, MD, Saad S. Kenderian, MD, Jose F. Leis, MD PhD, Yucai Wang, MD PhD, Amie Fonder, PA-C, MS, Min Shi, MD PhD, Daniel L. Van Dyke, PhD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3037.

https://doi.org/10.1182/blood-2019-131154

Published: 2019

Journal Articles

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2019) 134 (Supplement_1): 4306.

https://doi.org/10.1182/blood-2019-123824

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience

Kebede H. Begna, MD, Walid Ali, MD, Naseema Gangat, MBBS, Michelle A. Elliott, MD, Aref Al-Kali, MD, Mark R. Litzow, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, William J. Hogan, MBBCh, Mrinal M. Patnaik, MD MBBS, Animesh Pardanani, MBBS, PhD, Darci Zblewski, APRN, C-NP, Dong Chen, MD PhD, Rong He, MD, David S Viswanatha, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 2689.

https://doi.org/10.1182/blood-2018-99-110811

Published: 2018

Journal Articles

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Ayalew Tefferi, MD, Natasha Szuber, MD, Kebede H. Begna, MD, Mrinal M. Patnaik, MD MBBS, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS

Blood (2018) 132 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2018-99-116601

Published: 2018

Journal Articles

Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies

Maura Nicolosi, MD, Domenico Penna, MD, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Rhett P. Ketterling, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2018-99-109714

Published: 2018

Journal Articles

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

Domenico Penna, MD, Natasha Szuber, MD, Terra L. Lasho, PhD, Christy Finke, BS, Rangit Reddy Vallapureddy, MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2018-99-119910

Published: 2018

Journal Articles

20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients

Domenico Penna, MD, Maura Nicolosi, MD, Mythri Mudireddy, MBBS, Natasha Szuber, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 4301.

https://doi.org/10.1182/blood-2018-99-109718

Published: 2018

Journal Articles

Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients

Ni Fan, MD PhD, Sravanthi Lavu, MBBS, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 5457.

https://doi.org/10.1182/blood-2018-99-112587

Published: 2018

Journal Articles

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C Barrientos, MD, Harry P. Erba, MDPhD, Richard M. Stone, MD, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): LBA-4.

https://doi.org/10.1182/blood-2018-120779

Published: 2018

Journal Articles

Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS)

Geffen Kleinstern, PhD, Sara J. Achenbach, Dennis P. Robinson, Aaron D. Norman, Kari G. Chaffee, MS, Connie E. Lesnick, Sameer A. Parikh, MD, Timothy G. Call, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Tait D. Shanafelt, MD, Susan L. Slager, PhD

Blood (2018) 132 (Supplement 1): 5538.

https://doi.org/10.1182/blood-2018-99-116414

Published: 2018

Journal Articles

Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases

Animesh Pardanani, MBBS, PhD, Yoseph Elala, MD, Sahrish Shah, MD, Terra L. Lasho, PhD, Mrinal M. Patnaik, MDMBBS, Darci Zblewski, APRN, C-NP, Rhett P. Ketterling, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 582.

https://doi.org/10.1182/blood-2018-99-113914

Published: 2018

Journal Articles

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Ayalew Tefferi, MD, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giacomo Coltro, MD, Christy Finke, BS, Giuseppe Gaetano Loscocco, MD, Mythri Mudireddy, MBBS, Benedetta Sordi, MD, Natasha Szuber, MD, Giada Rotunno, PhD, Rangit Vallapureddy, MBBS, Annalisa Pacilli, PhD, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 578.

https://doi.org/10.1182/blood-2018-99-109715

Published: 2018

Journal Articles

Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis

Natasha Szuber, MD, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2018-99-117458

Published: 2018

Journal Articles

A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy

Naseema Gangat, MBBS, Amy Phelps, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Mrinal M. Patnaik, MD, MBBS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2018-99-109716

Published: 2018

Journal Articles

Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Reddy Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2018-99-117540

Published: 2018

NARROW

Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older

Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies

Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis

20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients

Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS)

Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis

A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy

Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only